3 Undervalued Diagnostics Stocks Trading Below Fair Value

India's diagnostics industry has grown on rising preventive healthcare awareness and expanding pathology lab networks, pushing valuations across the healthcare delivery space to a rich average price to earnings ratio. Not every stock in the space trades at the same multiple. A screen of listed diagnostics stocks against the sector's average price to earnings ratio surfaces three names still priced below that benchmark.

Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies all currently trade below the broader healthcare industry PE, despite posting positive return on equity. This piece breaks down why each stock screens as undervalued, what the underlying financials show, and the risks that come with owning diagnostic chain operators.

Click Here – Get Free Investment Predictions

Why These Diagnostics Stocks Screen as Undervalued

The healthcare delivery industry, which includes diagnostic chains, currently carries an average price to earnings ratio of close to 67.8 times trailing earnings. A stock trading meaningfully below that average, while still posting positive return on equity, is a reasonable starting point for a relative valuation screen.

All three companies below clear that bar, with Thyrocare Technologies standing out for the strongest return on equity of the group, a combination not always available among diagnostics stocks priced at a discount to the sector multiple.

The table below lists these three companies alongside their current price, valuation multiple and return ratios.

Company	NSE Ticker	CMP (Rs)	PE Ratio	Sector PE	ROE	Market Cap (Rs Cr)
Dr Lal PathLabs	LALPATHLAB	1,932.70	59.50	67.76	20.13%	32,510
Metropolis Healthcare	METROPOLIS	576.05	58.34	67.76	12.56%	11,833
Thyrocare Technologies	THYROCARE	582.50	54.77	67.76	27.85%	9,633

Dr Lal PathLabs: Largest Network Scale

Dr Lal PathLabs operates one of India's largest networks of pathology labs and collection centres across North and East India. The stock trades at a price to earnings ratio of 59.50, below the sector average of 67.76, at a current price of around Rs 1,933.

Return on equity of 20.13 percent is supported by a low debt to equity ratio of 0.08. On an EPS of Rs 32.55 and book value of Rs 149.45, the price to book multiple works out to 12.96, alongside a dividend yield of 1.06 percent.

Metropolis Healthcare: Mid Sized Pan India Presence

Metropolis Healthcare runs a network of pathology labs with a pan India presence and a focus on specialised and wellness testing. Its price to earnings ratio of 58.34 sits just below the sector average of 67.76, at a current share price of around Rs 576.

Return on equity of 12.56 percent is the most modest of the three diagnostics stocks, and the debt to equity ratio of 0.15 remains low. On an EPS of Rs 9.78 and book value of Rs 72.44, the price to book multiple works out to 7.88.

Thyrocare Technologies: Highest ROE, Widest Discount

Thyrocare Technologies operates a centralised processing lab model for diagnostic testing, focused on preventive health checks and wellness packages. The stock trades at 54.77 times trailing earnings, the widest discount to the sector average of 67.76 among these three diagnostics stocks, at a current price of around Rs 583.

Return on equity of 27.85 percent is the highest of the group by a wide margin, and the debt to equity ratio of 0.09 remains low. On an EPS of Rs 11.05 and book value of Rs 32.21, the price to book multiple of 18.79 is the richest among these three names, alongside a dividend yield of 2.31 percent.

Valuation Snapshot: PE, PB and Dividend Yield

Beyond the headline price to earnings ratio, book value multiples and dividend yield round out the valuation picture for these three companies. Thyrocare Technologies commands the richest price to book multiple, consistent with its markedly higher return on equity.

Company	Price to Book	Book Value (Rs)	Dividend Yield	Debt to Equity
Dr Lal PathLabs	12.96	149.45	1.06%	0.08
Metropolis Healthcare	7.88	72.44	0.88%	0.15
Thyrocare Technologies	18.79	32.21	2.31%	0.09

Thyrocare Technologies pays the highest dividend yield of the three despite its higher book value multiple, while Metropolis Healthcare trades at the most modest valuation of the group across both PE and PB metrics.

Check Live PE, PB and ROE Data on the Univest Screener

Risks to Consider Before Buying These Diagnostics Stocks

A discount to the sector average price to earnings ratio does not remove company specific risk for diagnostics stocks tied to test volumes and pricing.

Test Pricing and Competitive Intensity

Intense competition among diagnostic chains and standalone labs can pressure test pricing, particularly for routine and commoditised tests with low differentiation.

Franchise and Collection Centre Dependence

Much of the network expansion for these companies relies on franchise partners and collection centres, making quality control and brand consistency an ongoing operational challenge.

Regulatory and Accreditation Risk

Diagnostic labs operate under regulatory and quality accreditation requirements, and any lapses can affect reputation and patient trust across the network.

Seasonal and Wellness Package Demand Variability

Demand for preventive health checks and wellness packages can vary seasonally and with broader consumer sentiment, adding variability to quarterly test volumes.

How to Track These Diagnostics Stocks

Investors evaluating these three names should track quarterly test volume growth, realisation per test, and how the sector average PE moves relative to each company's own multiple over time, rather than relying on the valuation gap in isolation among diagnostics stocks. Comparing these numbers regularly is the most reliable way to judge whether the discount to fair value remains intact or has already closed.

Download the Univest iOS App or Univest Android App to track Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies share prices live and set price alerts.

Conclusion

Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies are the three diagnostics stocks currently trading below the sector's average price to earnings ratio of close to 67.8 times, while all three post positive return on equity. That combination makes them worth a closer look for investors who already want exposure to India's diagnostic testing theme, though pricing competition and franchise dependence mean position sizing and diversification still matter when adding these names to a portfolio.

FAQs on Undervalued Diagnostics Stocks

Which diagnostics stocks are trading below the sector average PE?

Ans. Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies are currently trading below the healthcare sector's average price to earnings ratio of close to 67.8 times, based on live NSE and BSE pricing.

Is Thyrocare Technologies undervalued compared to its sector?

Ans. Thyrocare Technologies trades at a price to earnings ratio of 54.77, the widest discount to the sector average of 67.76 among these three names, while delivering a return on equity of 27.85 percent.

Which of these diagnostics stocks has the highest return on equity?

Ans. Thyrocare Technologies has by far the highest return on equity of the three at 27.85 percent, ahead of Dr Lal PathLabs at 20.13 percent and Metropolis Healthcare at 12.56 percent.

What is the market capitalisation of Dr Lal PathLabs?

Ans. Dr Lal PathLabs has a market capitalisation of around Rs 32,510 crore, with a price to earnings ratio of 59.50 against the sector average of 67.76.

Which of these diagnostics stocks trades at the lowest valuation?

Ans. Metropolis Healthcare trades at the most modest valuation of the three, with a price to earnings ratio of 58.34 and a price to book multiple of 7.88, both lower than Dr Lal PathLabs and Thyrocare Technologies.

What are the main risks in undervalued diagnostics stocks?

Ans. The main risks include competitive pressure on test pricing, dependence on franchise and collection centre partners, regulatory and accreditation requirements, and seasonal variability in wellness package demand.

Is a low PE enough reason to buy a diagnostics stock?

Ans. A price to earnings ratio below the sector average is a useful starting screen for diagnostics stocks but not a standalone buy signal. Investors should also review test volume growth, network quality and pricing trends before investing.